Objective:
To investigate whether iris color influences the efficacy of low-dose atropine in myopia management.
Key Findings:
- Safety-related ocular effects of low-dose atropine appear consistent across different iris colors.
- At 24 months, children with non-brown irides showed significantly less myopia progression with atropine 0.01% compared to placebo.
- No significant treatment effect was observed in children with brown irides treated with atropine 0.01%.
- Differences in efficacy were not observed with atropine 0.05%.
- Pharmacokinetics may explain the differences, as atropine binds to melanin in the iris.
Interpretation:
Limitations:
- The analysis was post-hoc and not powered to detect subgroup differences.
- Variability between trials, including formulation differences, may have influenced results.
- Previous studies in predominantly Asian populations have shown efficacy with 0.01% atropine, indicating iris color alone may not explain treatment response.
Conclusion:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
